HomeNDC LookupIngredientsBisacodyl › 00132-0703-36
Fleet Bisacodyl 10 mg/30mL Enema, 37 mL — NDC 00132-0703-36 package photo

Fleet Bisacodyl 10 mg/30mL Enema, 37 mL

by C.B. Fleet Company, Inc. · 37 mL in 1 BOTTLE, WITH APPLICATOR (0132-0703-36)
NDC 00132-0703-36
🏷️ FDA NDC (as labeled) 0132-0703-36 billing pads the labeler segment with a zero
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 0132-0703-36
Product NDC 0132-0703
11-digit billing NDC 00132070336
NCPDP billing unit ML — per mL (volume)
RxCUI 308749
UNII 10X0709Y6I
Application # M007
SPL Set ID 324e61eb-8f6b-48d7-85c2-b1b5642691c9
Established class (EPC) Stimulant Laxative
Physiologic effect Increased Large Intestinal Motility; Stimulation Large Intestine Fluid/Electrolyte Secretion
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2002-05-10
Route RECTAL
Dosage form ENEMA
Substance BISACODYL
GPI-14 46200010005110
GPI class Fleet Bisacodyl
GCN Seq No 023908
GCN 08734
HICL code 001301
Ingredient (HICL) Bisacodyl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q3
Therapeutic class — intermediate (HIC2) Anal-Rectal Preparations
HIC3 code Q3S
Therapeutic class — specific (HIC3) Laxatives, Local/Rectal
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name FLEET BISACODYL 10 MG ENEMA
FDB brand name Bisacodyl
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 0132-0703-36 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00132-0703-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Stimulant Laxative class.

Pharmacologic class Stimulant Laxative
Drug family (ATC) Contact laxatives, Enemas
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerC.B. Fleet Company, Inc.
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code00132
First marketedMay 2002
Product typeHuman Otc Drug
Portfolio23 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name FLEET BISACODYL 10 MG ENEMA Ingredient Bisacodyl
📗 Our plain-language guide HelloPharmacist
  • It depends on which form you're using. Oral tablets (like Dulcolax Stimulant Laxative) usually take 6 to 12 hours, so many people take them at bedtime and get results in the mornin...
  • No — it's really important not to chew, crush, or break bisacodyl tablets. They have a special protective coating that helps them reach the right part of your gut without irritatin...
  • Can I chew or crush the tablet if I have trouble swallowing?
  • Milk and antacids can break down the protective coating on bisacodyl tablets too soon, before the medicine reaches where it needs to work. This can cause stomach irritation and mak...
📖 Read our full Bisacodyl guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII HHT01ZNK31
    Carbomer Homopolymer Type B is a synthetic polymer made from acrylic acid. It absorbs water and forms a gel, so it's used in medicines as a thickener, suspending agent, and to help create a smooth texture in creams, gels, and lotions.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 7JPC6Y25QS
    A synthetic nonionic surfactant, a type of cleaning agent used in pharmaceutical formulations. It functions as an emulsifier and solubilizer, helping mix water and oil-based ingredients and improving how the medicine dissolves and spreads in the body.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescarbomer 934P, glycerin, methylparaben, octoxynol-9, propylparaben, purified water, sodium hydroxide

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.065 $2.39 / 37 ml
Medicaid paysCMS SDUD · 12 mo $0.0813 $3.01 / 37 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Oct 2021 Sep 2022 Jan 2026 Aug 2026 $0.065 $0.056
▲ Up 8% over the last 11 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Fleet 10 mg/30mLthis 00132-0703-36 C.B. 37 ml $0.065 Availability likely
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2002
On the market since
May 2002
📍
2026
Currently FDA-listed
24 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 00132-0703-36, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
4.7K
Units reimbursed last 4 qtrs
3.1M
Gross reimbursed last 4 qtrs
$249.9K
Avg / prescription
$53.07
Avg / unit
$0.0813
Latest quarter Q4 2025
1.1KRx
Medicaid pays / mL
$0.0813
gross reimbursed
vs
NADAC / mL
$0.0646
acquisition cost
=
Spread
+$0.0167
+26% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
48% FFS 52% MCO
Fee-for-service · 2,270 Rx Managed care · 2,439 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: 56,758 units · 5,014 per 100k residents MT North Dakota: no data reported ND Minnesota: 67,784 units · 1,182 per 100k residents MN Wisconsin: 122,654 units · 2,075 per 100k residents WI Michigan: 64,202 units · 640 per 100k residents MI New York: 218,891 units · 1,118 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 920,362 units · 7,810 per 100k residents OH Pennsylvania: 561,328 units · 4,331 per 100k residents PA New Jersey: 32,486 units · 350 per 100k residents NJ Massachusetts: 123,555 units · 1,765 per 100k residents MA California: 235,726 units · 605 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 49,480 units · 2,502 per 100k residents NE Missouri: no data reported MO Kentucky: 8,089 units · 179 per 100k residents KY West Virginia: no data reported WV Virginia: 136,999 units · 1,572 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 251,970 units · 3,391 per 100k residents AZ New Mexico: no data reported NM Kansas: 44,437 units · 1,511 per 100k residents KS Arkansas: no data reported AR Tennessee: 80,586 units · 1,131 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: 99,759 units · 9,676 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
1799,676
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Delaware 9,676 /100k
2 Ohio 7,810 /100k
3 Montana 5,014 /100k
4 Pennsylvania 4,331 /100k
5 Arizona 3,391 /100k
6 Nebraska 2,502 /100k
7 Wisconsin 2,075 /100k
8 Massachusetts 1,765 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Fleet (this brand).

Top reported reactions

Nausea2,995
Constipation2,670
Fatigue2,386
Pain2,315
Vomiting2,180
Dyspnoea2,164
Diarrhoea1,917

Age at onset

Neonate16
Infant27
Child81
Adolescent72
Adult2,466
Elderly3,219

Reporter sex

34,649 reports
Male · 44%
Female · 56%
Unknown · 0%

Serious outcomes

Hospitalization17,140
Life-threatening2,293
Reports over time (by year) — tap or hover for the count & year
2021 2022 2024 2026 2,883 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
00132-0703-36 You're viewing this 37 mL in 1 BOTTLE, WITH APPLICATOR (0132-0703-36) 2002-05-10 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 30 words

Uses for relief of fecal impaction for relief of occasional constipation for removal of residue after barium administration This product usually produces a bowel movement in 5 to 20 minutes.

⏱️ Dosage and Administration 25 words

Directions Single Daily Dosage (per 24 hours) adults and children 12 years and over 1 bottle per day children under 12 years DO NOT USE

⚠️ Warnings 122 words

Warnings For rectal use only. Do not use when abdominal pain, nausea, or vomiting are present unless directed by a doctor. Ask a doctor before using this product if you have a sudden change in bowel habits lasting more than 2 weeks already used a laxative for more than 1 week This product may cause abdominal discomfort, faintness, rectal burning, and mild cramps.

Stop use and ask a doctor if you have • rectal bleeding • no bowel movement within 20 minutes of using this product. These symptoms may indicate a serious condition. If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 8 words

Active ingredient (in each 30 mL delivered dose)

🧪 Inactive Ingredients 12 words

Inactive ingredients carbomer 934P, glycerin, methylparaben, octoxynol-9, propylparaben, purified water, sodium hydroxide

🎯 Purpose 8 words

Purpose Bisacodyl 10 mg .............Stimulant laxative/ bowel cleanser

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.